-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $89

Benzinga·07/21/2026 13:46:52
Listen to the news
Guggenheim analyst Brad Canino maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $106 to $89.